Home » Posts tagged 'RO 7197597'
Tag Archives: RO 7197597
Giredestrant

Giredestrant
CAS 1953133-47-5
MF C27H31F5N4O MW 522.6 g/mol
3-[(1R,3R)-1-[2,6-difluoro-4-[[1-(3-fluoropropyl)azetidin-3-yl]amino]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-difluoropropan-1-ol
- 3-((1R,3R)-1-(2,6-Difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol
- (1R,3R)-1-[2,6-Difluoro-4-[[1-(3-fluoropropyl)-3-azetidinyl]amino]phenyl]-beta,beta-difluoro-1,3,4,9-tetrahydro-3-methyl-2H-pyrido[3,4-b]indole-2-propanol
Wilserdly, FDA 2026, APPROVALS 2026, GDC 9545, RG 6171, RO 7197597, 28P3DU6DB3
To treat adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor 1-mutated locally advanced or metastatic breast cancer whose disease has recurred during or after endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting
Giredestrant is an orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, giredestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.
Giredestrant, sold under the brand name Wilserdly, is an oral selective estrogen receptor degrader (SERD) used for the treatment of estrogen receptor-positive (ER+) breast cancer.[1][2] It is a potent, nonsteroidal compound that antagonizes estrogen effects by competitively binding to both wild-type and mutant estrogen receptors with nanomolar potency.[1][3] Giredestrant works by inducing an inactive conformation of the estrogen receptor ligand-binding domain and promoting proteasome-mediated degradation of the receptor protein.[1][4][5]
Research
In clinical trials, giredestrant has been evaluated in patients with ER+breast cancer , including those with ESR1 mutations, both as a single agent and in combination with other therapies.[2][6] Its orally bioavailable.[3][4]
SCHEME

PAT
WO2016097072 – TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
F HOFFMANN LA ROCHE – WO2016/97072, 2016, A1, https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016097072&_cid=P22-MWMY5D-43733-1
PAT
US20160175289 – Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
https://patentscope.wipo.int/search/en/detail.jsf?docId=US174233194&_cid=P22-MWMXSA-28614-1
SYN
Journal of Medicinal Chemistry, 2021, vol. 64, # 16, p. 11841 – 11856

SYN
https://www.sciencedirect.com/org/science/article/abs/pii/S1083616022002432
Organic Process Research & Development, Date: 18 March 2022, Pages: 568-582 Volume: Volume 26, Issue 3
GDC-9545 is a selective estrogen receptor degrader that is being developed as a treatment for ER+/HER2– breast cancer. A robust, convergent manufacturing process for GDC-9545 was developed. The process features a Wenker aziridine synthesis to produce the key starting material tryptamine 11, a highly efficient C–N coupling between aminoazetidine 9 and 2,6-difluoro-4-bromobenzaldehyde diethyl acetal (33) to construct key intermediate 10, and a crystallization-driven diastereoselective Pictet–Spengler reaction to furnish the active pharmaceutical ingredient GDC-9545·tartrate.

PATENTS
- Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereofPublication Number:US-12233052-B2Priority Date:2014-12-18Grant Date:2025-02-25
- Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereofPublication Number:EP-3760623-A1Priority Date:2014-12-18
- TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOFPublication Number:TW-I784255-BPriority Date:2014-12-18Grant Date:2022-11-21
- Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereofPublication Number:US-9980947-B2Priority Date:2014-12-18Grant Date:2018-05-29
- TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOFPublication Number:TW-I699363-BPriority Date:2014-12-18Grant Date:2020-07-21
- Tetrahydro-pyrido[3,4-b]indoles as estrogen receptor modulators and uses thereofPublication Number:EP-3233852-B1Priority Date:2014-12-18Grant Date:2020-07-15
- TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOFPublication Number:US-2025114338-A1Priority Date:2014-12-18
- Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereofPublication Number:JP-7446348-B2Priority Date:2014-12-18Grant Date:2024-03-08
- TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOFPublication Number:US-2016175289-A1Priority Date:2014-12-18
ADVERTISEMENT
ANAX LABORATORIES
WEBSITE https://www.anaxlab.com/
Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences
Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales
SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect

Phone : +91 897704 2010 / +91 9177075735, Email : info@anaxlab.com
#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma



AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE

join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com

| Clinical data | |
|---|---|
| Trade names | Wilserdly |
| Other names | GDC-9545, RG6171, RO7197597 |
| Identifiers | |
| IUPAC name | |
| CAS Number | 1953133-47-5 |
| PubChem CID | 121410806 |
| ChemSpider | 103748880 |
| UNII | 28P3DU6DB3 |
| KEGG | D11961 |
| ChEMBL | ChEMBL4650316 |
| Chemical and physical data | |
| Formula | C27H31F5N4O |
| Molar mass | 522.564 g·mol−1 |
| 3D model (JSmol) | Interactive image |
| SMILES | |
| InChI | |
References
- “Giredestrant (GDC-9545)”. Cancer.gov. U.S. National Cancer Institute. 14 November 2024.
- Malhi V, Agarwal P, Gates MR, Liu L, Wang J, De Bruyn T, et al. (December 2023). “Optimizing Early-stage Clinical Pharmacology Evaluation to Accelerate Clinical Development of Giredestrant in Advanced Breast Cancer”. Cancer Research Communications. 3 (12): 2551–2559. doi:10.1158/2767-9764.CRC-23-0324. PMC 10722959. PMID 38019116.
- “A clinical study to compare giredestrant with fulvestrant, both combined with a targeted therapy (CDK4/6 inhibitor) in people with ER-positive, HER2-negative breast cancer that has come back after adjuvant hormone therapy”. Roche.
- Jhaveri KL, Bellet M, Turner NC, Loi S, Bardia A, Boni V, et al. (February 2024). “Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer”. Clinical Cancer Research. 30 (4): 754–766. doi:10.1158/1078-0432.CCR-23-1796. PMC 10870118. PMID 37921755.
- Liang J, Zbieg JR, Blake RA, Chang JH, Daly S, DiPasquale AG, et al. (August 2021). “GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer”. Journal of Medicinal Chemistry. 64 (16): 11841–11856. doi:10.1021/acs.jmedchem.1c00847. PMID 34251202.
- Lawrence L (25 July 2024). “Giredestrant Bests Anastrozole in ER+, HER2- Early Breast Cancer”.
Further reading
- Gheysen M, Punie K, Wildiers H, Neven P (November 2024). “Oral SERDs changing the scenery in hormone receptor positive breast cancer, a comprehensive review”. Cancer Treatment Reviews. 130 102825. doi:10.1016/j.ctrv.2024.102825. PMID 39293125.
- Guglielmi G, Del Re M, Gol LS, Bengala C, Danesi R, Fogli S (April 2024). “Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer”. European Journal of Pharmacology. 969 176424. doi:10.1016/j.ejphar.2024.176424. hdl:2434/1128718. PMID 38402929.
- Garcia-Fructuoso I, Gomez-Bravo R, Schettini F (November 2022). “Integrating new oral selective oestrogen receptor degraders in the breast cancer treatment”. Current Opinion in Oncology. 34 (6): 635–642. doi:10.1097/CCO.0000000000000892. PMID 36000362.
- Chen YC, Yu J, Metcalfe C, De Bruyn T, Gelzleichter T, Malhi V, et al. (June 2022). “Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer”. Expert Opinion on Investigational Drugs. 31 (6): 515–529. doi:10.1080/13543784.2021.1983542. PMID 34694932.
- Martín M, Lim E, Chavez-MacGregor M, Bardia A, Wu J, Zhang Q, et al. (June 2024). “Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study”. Journal of Clinical Oncology. 42 (18): 2149–2160. doi:10.1200/JCO.23.01500. PMC 11185917. PMID 38537155.
/////////////Giredestrant, ANAX LABS, GDC 9545, RG 6171, RO 7197597, Wilserdly, FDA 2026, APPROVALS 2026, GDC-9545, RG6171, RO7197597, 28P3DU6DB3, breast cancer
#Giredestrant, #ANAX LABS, #GDC 9545, #RG 6171, #RO 7197597, #Wilserdly, #FDA 2026, #APPROVALS 2026, #GDC-9545, #RG6171, #RO7197597, #28P3DU6DB3, #breast cancer
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....










